A carregar...
Anticancer Drug Bortezomib Increases Interleukin-8 Expression in Human Monocytes
Bortezomib (BZ) is the first clinically approved proteasome inhibitor that has shown remarkable anticancer activity in patients with hematological malignancies. However, many patients relapse and develop resistance; yet, the molecular mechanisms of BZ resistance are not fully understood. We have rec...
Na minha lista:
| Publicado no: | Biochem Biophys Res Commun |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4410072/ https://ncbi.nlm.nih.gov/pubmed/25791477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbrc.2015.03.041 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|